News & Media /
Alfasigma USA Reintroduces IBS-C Drug Zelnorm to U.S. Market
Innovation Pharmaceuticals Announces License Agreement with Alfasigma S.p.A. for the Development and Commercialization of Brilacidin in Ulcerative Proctitis/Ulc...
Interview with Stefano Golinelli by Margherita Lopes - Adnkronos Salute’s PharmaKronos
You’re entering Alfasigma global website